Pharming (PHAR) EBITDA (2020 - 2026)

Pharming (PHAR) has 7 years of EBITDA data on file, last reported at -$3.6 million in Q2 2026.

• Quarterly EBITDA fell 94559889.75% year-over-year to -$3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.4 million (up 100.0% YoY) and the FY2025 annual result came in at $25.8 million, up 399.76% from the prior year.
• EBITDA retreated to -$3.6 million in Q2 2026, from -$0.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $4100.0 billion in Q3 2024 to a low of -$15300.0 billion in Q4 2024.
• A 5-year average of -$622.2 billion and a median of $1.9 in 2025 frame the typical range for EBITDA.
• The widest YoY moves for EBITDA: up 214884596.02% in 2024, down 235384615384515.38% in 2024.
• Tracing PHAR's EBITDA over 5 years: stood at $28.4 million in 2022, then slumped by 100.0% to -$6.5 in 2023, then plunged by 235384615384515.38% to -$15300.0 billion in 2024, then soared by 100.0% to $6.2 million in 2025, then sank by 158.03% to -$3.6 million in 2026.
• The last three EBITDA figures came in at -$3.6 million (Q2 2026), -$0.0 (Q1 2026), and $6.2 million (Q4 2025), per Business Quant data.